Medpace Holdings, Inc. $MEDP Stock Position Decreased by Engineers Gate Manager LP

Key Points

• Engineers Gate Manager LP cut its Medpace stake by 62% in the second quarter, selling 7,670 shares and retaining 4,693 shares valued at approximately $2.5 million.
• Medpace reported strong quarterly results, with EPS of $4.25 beating estimates and revenue rising 17.2% year over year to $707.33 million. The company issued fiscal 2026 EPS guidance of $17.25 to $17.95.
• Analyst sentiment remains cautious, with a consensus “Hold” rating and an average price target of $595.20, roughly in line with the stock’s reported $595.41 opening price.

Engineers Gate Manager LP lowered its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 62.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,693 shares of the company's stock after selling 7,670 shares during the quarter. Engineers Gate Manager LP's holdings in Medpace were worth $2,485,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. California State Teachers Retirement System increased its position in shares of Medpace by 53,619.6% in the second quarter. California State Teachers Retirement System now owns 13,989,649 shares of the company's stock worth $7,408,778,000 after acquiring an additional 13,963,607 shares in the last quarter. BlackRock Inc. purchased a new stake in shares of Medpace in the 2nd quarter valued at approximately $1,323,047,000. Geode Capital Management LLC lifted its position in shares of Medpace by 3.8% in the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company's stock valued at $374,836,000 after acquiring an additional 24,625 shares in the last quarter. Wasatch Advisors LP boosted its stake in Medpace by 19.4% in the 1st quarter. Wasatch Advisors LP now owns 773,931 shares of the company's stock worth $371,634,000 after purchasing an additional 125,625 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in Medpace by 8.3% in the 1st quarter. Renaissance Technologies LLC now owns 504,668 shares of the company's stock worth $242,337,000 after purchasing an additional 38,760 shares during the period. Institutional investors and hedge funds own 77.98% of the company's stock.

Medpace Price Performance

Shares of MEDP stock opened at $595.41 on Tuesday. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The stock's 50-day moving average is $579.61 and its two-hundred day moving average is $506.17. The firm has a market cap of $16.62 billion, a P/E ratio of 34.90, a PEG ratio of 2.62 and a beta of 1.15.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million during the quarter, compared to analysts' expectations of $689.51 million. During the same quarter in the previous year, the business posted $3.10 EPS. The firm's quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Wall Street Analyst Weigh In

MEDP has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft reissued a "hold" rating and set a $535.00 price target on shares of Medpace in a research report on Thursday, July 23rd. BMO Capital Markets raised their price objective on Medpace from $400.00 to $600.00 and gave the stock a "market perform" rating in a research report on Friday, July 24th. Mizuho lifted their target price on Medpace from $586.00 to $665.00 and gave the company an "outperform" rating in a research note on Friday, July 24th. Leerink Partners set a $620.00 target price on Medpace in a research note on Thursday, July 23rd. Finally, Robert W. Baird upped their target price on Medpace from $547.00 to $624.00 and gave the company a "neutral" rating in a report on Friday, July 24th. Three research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company's stock. According to data from MarketBeat, Medpace has a consensus rating of "Hold" and an average target price of $595.20.

Insider Buying and Selling at Medpace

In other news, Director Robert Kraft sold 3,858 shares of the stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $617.81, for a total transaction of $2,383,510.98. Following the transaction, the director owned 955 shares in the company, valued at $590,008.55. This represents a 80.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO August Troendle sold 650 shares of the stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $620.27, for a total transaction of $403,175.50. Following the transaction, the chief executive officer owned 539,894 shares in the company, valued at approximately $334,880,051.38. This trade represents a 0.12% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 134,471 shares of company stock valued at $82,151,311. 20.50% of the stock is currently owned by insiders.

Medpace Profile

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.